Small molecule PORCN inhibitors that block the biogenesis of Wnt ligands as well as antibodies that block Wnt function have been shown to inhibit tumor growth in preclinical models of RNF43-mutant pancreatic cancers (5, 11), and several have advanced into clinical trials (12). The gene discussed is PORCN; the disease is familial pancreatic carcinoma.